**C3RN News Summary – June 24, 2019**

Research­­­

1. A “review of the literature on medical cannabis use in pediatric and young adult cancer patients” finds that “the most common diagnoses were leukemia/lymphoma (36%), brain tumors (37%), and malignant solid tumors (26%). The most common indications were chemotherapy-related nausea, pain, and cancer cachexia.”

[June 17, 2019: Cancer and Blood Disorders Program, MN](https://www.mdpi.com/2227-9067/6/6/79/htm)

2. Researchers who posit that “addiction is characterized by an erosion of cognitive control toward drug taking” from the National Institutes of Health designed a study to test “the hypothesis that enhanced interference on cognitive control reflects a loss of segregation between cognition and emotion in addiction.” They conclude that “in CD (Cannabis Dependence), there was substantial overlap between cognitive and emotional brain-behavior associations, but in controls, associations were more restricted to the cognitive domain. These findings support our hypothesis of impaired segregation between cognitive and emotional processes in CD that might contribute to poor cognitive control under conditions of increased emotional demand.”

[June 18, 2019: National Institutes of Health, MD](https://academic.oup.com/cercor/advance-article/doi/10.1093/cercor/bhz113/5520075)

3. Researchers report “results of a retrospective cohort study of 661,617 women designed to assess associations between maternal cannabis use during pregnancy and adverse obstetrical and birth outcomes” reported finding “elevated rates of preterm birth… among those who reported cannabis use… While similar risks were observed for small-for-gestational-age birth and placental abruption, there appeared to be a small protective association between cannabis use and preeclampsia and gestational diabetes.”

[June 18, 2019: Boston University, MA](https://jamanetwork.com/journals/jama/article-abstract/2736581)

4. An academic review of articles relating to administration of cannabidiol alone “35 studies met inclusion criteria… 23 studies reported a significant improvement in primary outcomes (e.g. psychotic symptoms, anxiety, seizures)… Cannabidiol was reported as well tolerated and epilepsy was the most frequently studied medical condition, with all 11 studies demonstrating positive effects of cannabidiol on reducing seizure frequency or severity... There was no signal of positive activity of CBD in… assessing diabetes, Crohn's disease, ocular hypertension, fatty liver disease or chronic pain. However, low doses… were used in these studies.”

[June 20, 2019: Artelo Biosciences, CA](https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.14038)

Industry News

1. “The **U.S. House of Representatives** voted in favor of an **amendment** that would [stop the federal government](https://www.benzinga.com/markets/cannabis/19/06/13944844/federal-measures-to-protect-cannabis-users-in-legal-states-head-to-house-floor?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site) and its agencies from interfering with legal cannabis programs, individuals and businesses in compliance with state, territorial or tribal cannabis laws. In addition, the House passed amendments that would take $5 million in DEA funding and allocate it to an opioid recovery treatment program, and would instruct the FDA to regulate CBD products as conventional foods and dietary supplements.”

[June 23, 2019: Yahoo](https://finance.yahoo.com/news/week-cannabis-house-takes-historic-191226567.html)